

# Francesco Saia,, Fesc

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2379800/publications.pdf>

Version: 2024-02-01

201  
papers

9,304  
citations

44069

48  
h-index

43889

91  
g-index

223  
all docs

223  
docs citations

223  
times ranked

7890  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pattern of arterial inflammation and inflammatory markers in people living with HIV compared with uninfected people. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 1566-1575.	2.1	7
2	Management and outcomes of patients with left atrial appendage thrombus prior to percutaneous closure. <i>Heart</i> , 2022, 108, 1098-1106.	2.9	22
3	Balloon pulmonary angioplasty after pulmonary thromboendarterectomy. <i>Annals of Cardiothoracic Surgery</i> , 2022, 11, 192-194.	1.7	3
4	Therapeutic alternatives in chronic thromboembolic pulmonary hypertension: from pulmonary endarterectomy to balloon pulmonary angioplasty to medical therapy. State of the art from a multidisciplinary team. <i>Annals of Cardiothoracic Surgery</i> , 2022, 11, 120-127.	1.7	3
5	Peripheral intravascular lithotripsy for transcatheter aortic valve implantation: a multicentre observational study. <i>EuroIntervention</i> , 2022, 17, e1397-e1406.	3.2	21
6	Contemporary balloon aortic valvuloplasty: Changing indications and refined technique. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E1033-E1042.	1.7	7
7	Transcatheter Mitral Valve Replacement After Surgical Repair or Replacement. <i>Circulation</i> , 2021, 143, 104-116.	1.6	94
8	Women and transcatheter aortic valve implantation: Also a mismatch could be tomorrow's best match. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 527-528.	1.7	0
9	Innovative transcatheter procedures for the treatment of heart failure. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 292-300.	1.7	2
10	Safety, efficacy and impact on frailty of mini-invasive radial balloon aortic valvuloplasty. <i>Heart</i> , 2021, 107, 874-880.	2.9	13
11	Long-term echocardiographic findings after TAVR: 5-year follow-up in 400 consecutive patients. <i>Internal and Emergency Medicine</i> , 2021, 16, 1873-1882.	2.0	1
12	Combined Procedure of Percutaneous Mitral Valve Repair and Left Atrial Appendage Occlusion. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 590-592.	2.9	5
13	ST-Segment Elevation Myocardial Infarction Following Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2187-2199.	2.8	35
14	Sex based analysis of the impact of red blood cell transfusion and vascular or bleeding complications related to TAVI â€” The TRITAVI-Women Study. <i>International Journal of Cardiology</i> , 2021, 333, 69-76.	1.7	7
15	Impact on clinical outcomes of right ventricular response to percutaneous correction of secondary mitral regurgitation. <i>European Journal of Heart Failure</i> , 2021, 23, 1765-1774.	7.1	13
16	Transcatheter Aortic Valve Replacement for Pure Aortic Regurgitation in a LargeÂand Noncalcified Annulus. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, e271-e273.	2.9	7
17	Setting a benchmark for resource utilization and quality of care in patients undergoing transcatheter aortic valve implantation in Europeâ€”Rationale and design of the international <sc>BENCHMARK</sc> registry. <i>Clinical Cardiology</i> , 2021, 44, 1344-1353.	1.8	8
18	How to reduce uncommon but severe transcatheter aortic valve implantation complications: stroke, thrombosis, endocarditis, cognitive decline?. <i>European Heart Journal Supplements</i> , 2021, 23, E142-E146.	0.1	0

#	ARTICLE	IF	CITATIONS
19	Transcatheter edge-to-edge mitral valve repair: Should we stay tied to COAPT tiers?. Catheterization and Cardiovascular Interventions, 2021, 98, 1413-1414.	1.7	0
20	Coronary artery disease and reasonably incomplete coronary revascularization in high-risk patients undergoing transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2020, 95, 19-27.	1.7	15
21	Mid-term outcome in patients with bicuspid aortic valve stenosis following transcatheter aortic valve replacement with a current generation device: A multicenter study. Catheterization and Cardiovascular Interventions, 2020, 95, 1186-1192.	1.7	12
22	Timing of Oral P2Y12 Inhibitor Administration in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2020, 76, 2450-2459.	2.8	64
23	MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry. Journal of Heart and Lung Transplantation, 2020, 39, 1353-1362.	0.6	75
24	Downstream or upstream administration of P2Y12 receptor blockers in non-ST elevated acute coronary syndromes: study protocol for a randomized controlled trial. Trials, 2020, 21, 966.	1.6	1
25	Prespecified Risk Criteria Facilitate Adequate Discharge and Long-Term Outcomes After Transfemoral Transcatheter Aortic Valve Implantation. Journal of the American Heart Association, 2020, 9, e016990.	3.7	8
26	Optical coherence tomography assessment of macrophages accumulation in non-ST-segment elevation acute coronary syndromes. Journal of Cardiovascular Medicine, 2020, 21, 860-865.	1.5	4
27	Transcatheter Aortic Valve Replacement for Residual Lesion of the Aortic Valve Following "Healed" Infective Endocarditis. JACC: Cardiovascular Interventions, 2020, 13, 1983-1996.	2.9	15
28	Routine minimalist transcatheter aortic valve implantation with local anesthesia only. Journal of Cardiovascular Medicine, 2020, 21, 805-811.	1.5	11
29	Target Lesion Failure With Current Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2020, 13, 2868-2878.	2.9	22
30	Early Adverse Impact of Transfusion After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2020, 13, e009026.	3.9	17
31	Suprasternal access for transcatheter aortic valve implantation: All ways lead to Rome. Catheterization and Cardiovascular Interventions, 2020, 95, 1184-1185.	1.7	0
32	Modifications of medical treatment and outcome after percutaneous correction of secondary mitral regurgitation. ESC Heart Failure, 2020, 7, 1753-1763.	3.1	8
33	Long-term percentage of ventricular pacing in patients requiring pacemaker implantation after transcatheter aortic valve replacement: A multicenter 10-year experience. Heart Rhythm, 2020, 17, 1897-1903.	0.7	6
34	Impact of Elective, Uncomplicated Target Lesion Revascularization on Cardiac Mortality After Elective Percutaneous Coronary Intervention of Unprotected Left Main Coronary Artery Disease. American Journal of Cardiology, 2020, 128, 94-100.	1.6	0
35	Reply. JACC: Cardiovascular Interventions, 2020, 13, 1382-1383.	2.9	0
36	Predicting and improving outcomes of transcatheter aortic valve replacement in older adults and the elderly. Expert Review of Cardiovascular Therapy, 2020, 18, 663-680.	1.5	3

#	ARTICLE	IF	CITATIONS
37	Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves. <i>European Heart Journal</i> , 2020, 41, 2731-2742.	2.2	97
38	Long-term outcome of prosthesis-patient mismatch after transcatheter aortic valve replacement. <i>International Journal of Cardiology</i> , 2020, 318, 27-31.	1.7	13
39	Transcatheter aortic valve implantation (TAVI) in cardiogenic shock: TAVIâ€šock registry results. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1128-1135.	1.7	14
40	Balloon Aortic Valvuloplasty Today. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 592-593.	2.9	2
41	Coronary Protection to Prevent Coronary Obstruction During TAVR. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 739-747.	2.9	58
42	Impact of coronary bypass or stenting on mortality and myocardial infarction in stable coronary artery disease. <i>International Journal of Cardiology</i> , 2020, 309, 63-69.	1.7	4
43	Rapid pacing using device programmers: A complex procedural simplification?. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 1049-1050.	1.7	1
44	MitraClip Treatment of Secondary Mitral Regurgitation in Heart Failure with Reduced Ejection Fraction: Lessons and Implications from Trials and Registries. <i>Structural Heart</i> , 2020, 4, 247-253.	0.6	5
45	In-hospital and thirty-day outcomes of the SAPIEN 3 Ultra balloon-expandable transcatheter aortic valve: the S3U registry. <i>EuroIntervention</i> , 2020, 15, 1240-1247.	3.2	47
46	Multi-Imaging Investigation to Evaluate the Relationship between Serum Cystatin C and Features of Atherosclerosis in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Applied Sciences (Switzerland)</i> , 2019, 9, 657.	2.5	0
47	Bring the old boysâ€”and girlsâ€”Back home. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 456-457.	1.7	1
48	Left Main Coronary Artery Extrinsic Compression in Patients With Pulmonary Arterial Hypertension. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 319-321.	2.9	10
49	Shifting the attention from devices to treatment: the lesson from IABP-SHOCK II and other trials in cardiogenic shock. <i>Journal of Thoracic Disease</i> , 2019, 11, E206-E209.	1.4	1
50	Efficacy and safety of thrombus aspiration in ST-segment elevation myocardial infarction: an updated systematic review and meta-analysis of randomised clinical trials. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 24-38.	1.0	11
51	Optimising patient discharge management after transfemoral transcatheter aortic valve implantation: the multicentre European FAST-TAVI trial. <i>EuroIntervention</i> , 2019, 15, 147-154.	3.2	70
52	Surgical Risk Scores Applied to Transcatheter Aortic Valve Implantation: Friends or Foes? Short-Term and Long-Term Outcomes From a Single-Center Registry. <i>Journal of Invasive Cardiology</i> , 2019, 31, E282-E288.	0.4	4
53	A Multidisciplinary Approach on theÂPerioperative Antithrombotic ManagementÂof Patients With CoronaryÂStents Undergoing Surgery. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 417-434.	2.9	81
54	Transcatheter Mitral Valve-in-Valve Dislocation: AÂRescue Strategy. <i>Annals of Thoracic Surgery</i> , 2018, 106, e137-e139.	1.3	0

#	ARTICLE	IF	CITATIONS
55	Predicting device failure after percutaneous repair of functional mitral regurgitation in advanced heart failure: Implications for patient selection. International Journal of Cardiology, 2018, 257, 182-187.	1.7	26
56	Randomized comparison of balloon aortic valvuloplasty performed with or without rapid cardiac pacing: The pacing versus no pacing (PNP) study. Journal of Interventional Cardiology, 2018, 31, 51-59.	1.2	9
57	Vascular complications after balloon aortic valvuloplasty in recent years: Incidence and comparison of two hemostatic devices. Catheterization and Cardiovascular Interventions, 2018, 91, E49-E55.	1.7	13
58	Prognostic significance of shockable and non-shockable cardiac arrest in ST-segment elevation myocardial infarction patients undergoing primary angioplasty. Resuscitation, 2018, 123, 8-14.	3.0	6
59	Prodromal angina and risk of 2-year cardiac mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention. Medicine (United States), 2018, 97, e12332.	1.0	2
60	Temporal course of vascular healing and neoatherosclerosis after implantation of durable- or biodegradable-polymer drug-eluting stents. European Heart Journal, 2018, 39, 2448-2456.	2.2	44
61	Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet, The, 2018, 392, 835-848.	13.7	215
62	Evolution of STEMI network in Italy. Minerva Cardiology and Angiology, 2018, 66, 392-399.	0.7	1
63	Incidence, treatment, and outcome of acute aortic valve regurgitation complicating percutaneous balloon aortic valvuloplasty. Catheterization and Cardiovascular Interventions, 2017, 89, E145-E152.	1.7	22
64	Transcatheter aortic valve implantation in low ejection fraction/low transvalvular gradient patients. Journal of Cardiovascular Medicine, 2017, 18, 103-108.	1.5	13
65	Does pre-existing aortic regurgitation protect from death in patients who develop paravalvular leak after TAVI?. International Journal of Cardiology, 2017, 233, 52-60.	1.7	18
66	Utility of stress perfusion-cardiac magnetic resonance in follow-up of patients undergoing percutaneous coronary interventions of the left main coronary artery. International Journal of Cardiovascular Imaging, 2017, 33, 1589-1597.	1.5	4
67	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management. Journal of the American College of Cardiology, 2017, 69, 2592-2603.	2.8	132
68	Relation between thoracic aortic inflammation and features of plaque vulnerability in the coronary tree in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. An FDG-positron emission tomography and optical coherence tomography study. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1878-1887.	6.4	9
69	Left Main Coronary Artery Compression in Patients With Pulmonary Arterial Hypertension and Angina. Journal of the American College of Cardiology, 2017, 69, 2808-2817.	2.8	91
70	Cognitive functions: evaluation and changes after transcatheter aortic valve implantation in elderly patients. Future Cardiology, 2017, 13, 229-237.	1.2	3
71	Twelve-month outcome of patients with an established indication for oral anticoagulation undergoing coronary artery stenting and stratified by the baseline risk of bleeding. Cardiovascular Revascularization Medicine, 2017, 18, 425-430.	0.8	11
72	Role of residual acute stent malapposition in percutaneous coronary interventions. Catheterization and Cardiovascular Interventions, 2017, 90, 566-575.	1.7	42

#	ARTICLE	IF	CITATIONS
73	Fate of Nonculprit Plaques in Patients With STEMI Undergoing Primary PCI Followed by Statin Therapy. JACC: Cardiovascular Imaging, 2017, 10, 827-829.	5.3	3
74	Comparative assessment of "plaque/media" change on three modalities of IVUS immediately after implantation of either everolimus-eluting bioresorbable vascular scaffold or everolimus-eluting metallic stent in Absorb II study. International Journal of Cardiovascular Imaging, 2017, 33, 441-449.	1.5	3
75	Relationship between Serum Inflammatory Biomarkers and Thrombus Characteristics in Patients with ST Segment Elevation Myocardial Infarction. Cardiology, 2017, 137, 27-35.	1.4	5
76	Reply. Journal of the American College of Cardiology, 2017, 70, 2460-2461.	2.8	1
77	Percutaneous mitral valve repair: The last chance for symptoms improvement in advanced refractory chronic heart failure?. International Journal of Cardiology, 2017, 228, 191-197.	1.7	40
78	Feasibility and safety of early discharge after transfemoral transcatheter aortic valve implantation "rationale and design of the FAST-TAVI registry. BMC Cardiovascular Disorders, 2017, 17, 259.	1.7	19
79	Surgery after drug-eluting stent implantation: it's not all doom and gloom!. Journal of Thoracic Disease, 2017, 9, E373-E377.	1.4	9
80	Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry. EuroIntervention, 2017, 13, 459-466.	3.2	83
81	How should I treat an unexpected deadlock at the time of transcatheter aortic valve prosthesis implantation?. EuroIntervention, 2017, 13, e256-e258.	3.2	0
82	Transcatheter subclavian versus transapical access for transcatheter aortic valve implantation: A multicenter study. Catheterization and Cardiovascular Interventions, 2016, 87, 332-338.	1.7	46
83	Impact of Culprit Plaque and Atherothrombotic Components on Incomplete Stent Apposition in Patients With ST-Elevation Myocardial Infarction Treated With Everolimus-Eluting Stents "An OCTAVIA Substudy ". Circulation Journal, 2016, 80, 895-905.	1.6	5
84	Prevalence and Impact of Atrial Fibrillation in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2016, 9, 937-946.	2.9	145
85	Bicuspid Aortic Valve Stenosis. JACC: Cardiovascular Interventions, 2016, 9, 817-824.	2.9	147
86	Early and mid-term outcomes of 1904 patients undergoing transcatheter balloon-expandable valve implantation in Italy: results from the Italian Transcatheter Balloon-Expandable Valve Implantation Registry (ITER). European Journal of Cardio-thoracic Surgery, 2016, 50, 1139-1148.	1.4	32
87	Predictive ability of the CHADS <sub>2</sub> and CHA <sub>2</sub> DS <sub>2</sub> -VASc scores for stroke after transcatheter aortic balloon-expandable valve implantation: an Italian Transcatheter Balloon-Expandable Valve Implantation Registry (ITER) sub-analysis. European Journal of Cardio-thoracic Surgery, 2016, 50, 867-873.	1.4	11
88	Risk of Adverse Cardiac and Bleeding Events Following Cardiac and Noncardiac Surgery in Patients With Coronary Stent. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 39-47.	2.2	40
89	Coexistence of Degenerative Aortic Stenosis and Wild-Type Transthyretin-Related Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2016, 9, 325-327.	5.3	89
90	Risk of Stroke in Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention versus Optimal Medical Therapy: Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2016, 11, e0158769.	2.5	2

#	ARTICLE	IF	CITATIONS
91	Balloon aortic valvuloplasty as a bridge-to-decision in high risk patients with aortic stenosis: a new paradigm for the heart team decision making. Journal of Geriatric Cardiology, 2016, 13, 475-82.	0.2	15
92	New generation drug-eluting stents reduce stent thrombosis and myocardial infarction: A propensity score-adjusted analysis from the multicenter REAL registry (REgistro Regionale) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702 797-806.	1.7	5
93	Management and outcome of major bleeding in patients on triple therapy after coronary stenting. Clues from the WARfarin and coronary STENTing (WAR-STENT) registry. Journal of Cardiovascular Medicine, 2015, 16, 520-521.	1.5	1
94	Eroded Versus Ruptured Plaques at the Culprit Site of STEMI. JACC: Cardiovascular Imaging, 2015, 8, 566-575.	5.3	88
95	Reply. JACC: Cardiovascular Interventions, 2015, 8, 869-870.	2.9	0
96	Comparison of Balloon-Expandable Versus Self-Expandable Valves for Transcatheter Aortic Valve Implantation in Patients With Low-Gradient Severe Aortic Stenosis and Preserved Left Ventricular Ejection Fraction. American Journal of Cardiology, 2015, 115, 810-815.	1.6	6
97	Long-Term Outcomes of Percutaneous Paravalvular Regurgitation Closure After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2015, 8, 681-688.	2.9	43
98	Interplay of coronary angiography and intravascular ultrasound in predicting long-term outcomes after heart transplantation. Journal of Heart and Lung Transplantation, 2015, 34, 1146-1153.	0.6	45
99	In the era of the valve-in-valve: is transcatheter aortic valve implantation (TAVI) in sutureless valves feasible?. Annals of Cardiothoracic Surgery, 2015, 4, 214-7.	1.7	29
100	Repeated Aortic Balloon Valvuloplasty in Elderly Patients With Aortic Stenosis Who Are Not Candidates for Definitive Treatment. Journal of Invasive Cardiology, 2015, 27, E277-84.	0.4	5
101	Causes and timing of death during long-term follow-up after transcatheter aortic valve replacement. American Heart Journal, 2014, 168, 798-806.	2.7	36
102	Usefulness and Validation of the Survival post TAVI Score for Survival After Transcatheter Aortic Valve Implantation for Aortic Stenosis. American Journal of Cardiology, 2014, 114, 1867-1874.	1.6	30
103	Risk of Stroke in Patients With High On-Clopidogrel Platelet Reactivity to Adenosine Diphosphate After Percutaneous Coronary Intervention. American Journal of Cardiology, 2014, 113, 1807-1814.	1.6	5
104	Diagnostic performance of standard electrocardiogram for prediction of infarct related artery and site of coronary occlusion in unselected STEMI patients undergoing primary percutaneous coronary intervention. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 326-339.	1.0	22
105	Mechanisms of Atherothrombosis and Vascular Response to Primary Percutaneous Coronary Intervention in Women Versus Men With Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2014, 7, 958-968.	2.9	89
106	Transcatheter aortic valve implantation for severe autograft regurgitation after Ross operation. EuroIntervention, 2014, 10, 141-145.	3.2	5
107	Cardiac FDG PET/CT is useful to assess the culprit lesion in nonST-segment elevation myocardial infarction (NSTEMI). European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 642-643.	6.4	0
108	Invited Commentary. Annals of Thoracic Surgery, 2013, 96, 1328.	1.3	0



#	ARTICLE	IF	CITATIONS
109	Gender-related differences of diabetic patients undergoing percutaneous coronary intervention with drug-eluting stents: A real-life multicenter experience. International Journal of Cardiology, 2013, 168, 139-143.	1.7	12
110	Incidence and Outcome of High On-Treatment Platelet Reactivity in Patients With Non-ST Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the VIP) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702 T 792-798.	1.6	12
111	Paclitaxel versus sirolimus eluting stents in diabetic patients: Does stent type and/or stent diameter matter?: Long-term clinical outcome of 2,429 patient multicenter registry. Catheterization and Cardiovascular Interventions, 2013, 81, 80-89.	1.7	15
112	Acute kidney injury following transcatheter aortic valve implantation: incidence, predictors and clinical outcome. International Journal of Cardiology, 2013, 168, 1034-1040.	1.7	103
113	Baseline White Blood Cell Count Is an Independent Predictor of Long-Term Cardiovascular Mortality in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome, but It Does Not Improve the Risk Classification of the GRACE Score. Cardiology, 2013, 124, 97-104.	1.4	14
114	Coronary artery bypass grafting vs percutaneous coronary intervention in a 'real-world' setting: a comparative effectiveness study based on propensity score-matched cohorts. European Journal of Cardio-thoracic Surgery, 2013, 44, e16-e24.	1.4	35
115	Impact of COPD on Long-term Outcome After ST-Segment Elevation Myocardial Infarction Receiving Primary Percutaneous Coronary Intervention. Chest, 2013, 144, 750-757.	0.8	86
116	Predictors of complicated athero-thrombotic lesions in non-ST segment acute coronary syndrome. Journal of Cardiovascular Medicine, 2013, 14, 430-437.	1.5	3
117	Paclitaxel and sirolimus eluting stents in older patients with diabetes mellitus. Catheterization and Cardiovascular Interventions, 2013, 81, 1117-1124.	1.7	8
118	Emerging indications, in-hospital and long-term outcome of balloon aortic valvuloplasty in the transcatheter aortic valve implantation era. EuroIntervention, 2013, 8, 1388-1397.	3.2	84
119	Percutaneous treatment of paravalvular leaks after transcatheter aortic valve implantation with the CoreValve self-expanding bioprosthesis. EuroIntervention, 2013, 9, 292-292.	3.2	2
120	Quantification of scientific output in cardiovascular medicine: a perspective based on global data. EuroIntervention, 2013, 9, 975-978.	3.2	4
121	Residual aortic regurgitation is a major determinant of late mortality after transcatheter aortic valve implantation. International Journal of Cardiology, 2012, 157, 288-289.	1.7	19
122	Incidence, treatment and outcome of acute coronary syndromes: A community-based study in the era of myocardial infarction networks. International Journal of Cardiology, 2012, 157, 419-422.	1.7	3
123	Transradial Versus Transfemoral Intervention for Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2012, 5, 23-35.	2.9	101
124	Transcatheter aortic valve implantation with a self-expanding nitinol bioprosthesis. Catheterization and Cardiovascular Interventions, 2012, 79, 712-719.	1.7	37
125	Antithrombotic Management and 1-Year Outcome of Patients on Oral Anticoagulation Undergoing Coronary Stent Implantation (from the Registro Regionale Angioplastiche Emilia-Romagna Registry). American Journal of Cardiology, 2012, 109, 1411-1417.	1.6	30
126	Is balloon aortic valvuloplasty safe in patients with significant aortic valve regurgitation?. Catheterization and Cardiovascular Interventions, 2012, 79, 315-321.	1.7	10



#	ARTICLE	IF	CITATIONS
127	Safety and efficacy of early aggressive versus cholesterol-driven lipid-lowering strategies in heart transplantation: A pilot, randomized, intravascular ultrasound study. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 1305-1311.	0.6	20
128	Prognostic significance of mean platelet volume on admission in an unselected cohort of patients with non ST-segment elevation acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2011, 106, 132-140.	3.4	38
129	Prognostic Impact of Hospital Readmissions After Primary Percutaneous Coronary Intervention. <i>Archives of Internal Medicine</i> , 2011, 171, 1948.	3.8	41
130	Short- and Long-Term Prognostic Significance of ST-Segment Elevation in Lead aVR in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2011, 108, 21-28.	1.6	47
131	Incidence, prognostic value and management of vascular complications with transfemoral transcatheter aortic valve implantation. <i>Future Cardiology</i> , 2011, 7, 321-331.	1.2	12
132	Impact of a territorial ST-segment elevation myocardial infarction network on prognosis of patients with out-of-hospital cardiac arrest. <i>Acute Cardiac Care</i> , 2011, 13, 143-147.	0.2	4
133	Pre-hospital ECG in patients undergoing primary percutaneous interventions within an integrated system of care: reperfusion times and long-term survival benefits. <i>EuroIntervention</i> , 2011, 7, 449-457.	3.2	12
134	The role of percutaneous balloon aortic valvuloplasty as a bridge for transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2011, 7, 723-729.	3.2	63
135	Displacement of calcium nodules of the native valve as a possible cause of left main occlusion following transcatheter aortic valve implantation. <i>Journal of Invasive Cardiology</i> , 2011, 23, E106-9.	0.4	18
136	How many patients with severe symptomatic aortic stenosis excluded for cardiac surgery are eligible for transcatheter heart valve implantation?. <i>Journal of Cardiovascular Medicine</i> , 2010, 11, 727-732.	1.5	25
137	Safety and Efficacy of the Subclavian Approach for Transcatheter Aortic Valve Implantation With the CoreValve Revalving System. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 359-366.	3.9	272
138	Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. <i>European Heart Journal</i> , 2010, 31, 35-49.	2.2	103
139	Long-term outcome after drug eluting stenting in patients with ST-segment Elevation Myocardial Infarction. <i>International Journal of Cardiology</i> , 2010, 140, 154-160.	1.7	19
140	Management of acute left ventricular dysfunction after primary percutaneous coronary intervention for ST elevation acute myocardial infarction. <i>American Heart Journal</i> , 2010, 160, S16-S21.	2.7	12
141	Lower long-term mortality within a regional system of care for ST-elevation myocardial infarction. <i>Acute Cardiac Care</i> , 2010, 12, 42-50.	0.2	10
142	Long-term clinical follow-up of drug-eluting stent restenosis treatment: retrospective analysis from two high volume catheterisation laboratories. <i>EuroIntervention</i> , 2010, 5, 703-708.	3.2	27
143	Long-term clinical outcomes and cost-effectiveness analysis in multivessel percutaneous coronary interventions: comparison of drug-eluting stents, bare-metal stents and a mixed approach in patients at high and low risk of repeat revascularisation. <i>EuroIntervention</i> , 2010, 5, 953-961.	3.2	9
144	Twenty-four months clinical outcomes of sirolimus-eluting stents for the treatment of small coronary arteries: the long-term SES-SMART clinical study. <i>European Heart Journal</i> , 2009, 30, 2095-2101.	2.2	31

#	ARTICLE	IF	CITATIONS
145	Left Ventricular Function After ST-Elevation Myocardial Infarction in Patients Treated With Primary Percutaneous Coronary Intervention and Abciximab or Tirofiban (from the Facilitated Angioplasty) Tj ETQq1 1 0.784314 rgBT8/Overlook		
146	Safety and Efficacy of Drug-Eluting and Bare Metal Stents. Circulation, 2009, 119, 3198-3206.	1.6	794
147	Patient selection to enhance the long-term benefit of first generation drug-eluting stents for coronary revascularisation procedures. Insights from a large multicentre registry. EuroIntervention, 2009, 5, 57-66.	3.2	11
148	Long-Term Outcomes With Drug-Eluting Stents Versus Bare Metal Stents in the Treatment of Saphenous Vein Graft Disease (Results from the REgistro Regionale AngiopLastiche Emilia-Romagna) Tj ETQq0 0 0 rgBT /Overlook 10 Tf		
149	Optimisation of therapeutic strategies for ST-segment elevation acute myocardial infarction: the impact of a territorial network on reperfusion therapy and mortality. Heart, 2008, 95, 370-376.	2.9	45
150	Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial. European Heart Journal, 2008, 29, 2972-2980.	2.2	41
151	Long-term effectiveness of early administration of glycoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous interventions: results of a registry study in an ST-elevation myocardial infarction network. European Heart Journal, 2008, 30, 33-43.	2.2	45
152	Review: The safety of drug-eluting stents. Therapeutic Advances in Cardiovascular Disease, 2008, 2, 43-52.	2.1	6
153	Two-Year Clinical Outcomes With Drug-Eluting Stents for Diabetic Patients With De Novo Coronary Lesions. Circulation, 2008, 117, 923-930.	1.6	66
154	The conundrum of transient cortical blindness following coronary angiography. Journal of Cardiovascular Medicine, 2008, 9, 1063-1065.	1.5	14
155	Drug-eluting stents show delayed healing: paclitaxel more pronounced than sirolimus. European Heart Journal, 2007, 28, 974-979.	2.2	107
156	Predictive value of high sensitivity C-reactive protein in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention. European Heart Journal, 2007, 29, 1241-1249.	2.2	46
157	Long-Term Safety and Efficacy of Drug-Eluting Stents. Circulation, 2007, 115, 3181-3188.	1.6	138
158	Clinical comparison of "normal-hours" vs "off-hours" percutaneous coronary interventions for ST-elevation myocardial infarction. American Heart Journal, 2007, 154, 366-372.	2.7	40
159	Randomized comparative trial of a thin-strut bare metal cobalt-chromium stent versus a sirolimus-eluting stent for coronary revascularization. Catheterization and Cardiovascular Interventions, 2007, 69, 790-798.	1.7	30
160	Usefulness of Prehospital Triage in Patients With Cardiogenic Shock Complicating ST-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2007, 100, 787-792.	1.6	45
161	Clinical Outcomes for Sirolimus-Eluting Stents and Polymer-Coated Paclitaxel-Eluting Stents in Daily Practice. Journal of the American College of Cardiology, 2006, 48, 1312-1318.	2.8	41
162	Clinical imaging of the vulnerable plaque in the coronary arteries: new intracoronary diagnostic methods. Journal of Cardiovascular Medicine, 2006, 7, 21-28.	1.5	12

#	ARTICLE	IF	CITATIONS
163	Safety and Long-Term Efficacy of Sirolimus Eluting Stent in ST-elevation Acute Myocardial Infarction: The REAL (Registro REgionale AngiopLastiche Emilia-Romagna) Registry. Cardiovascular Drugs and Therapy, 2006, 20, 63-68.	2.6	16
164	Comparison Between Coronary Angioplasty and Coronary Artery Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Stenosis (the Bologna Registry). American Journal of Cardiology, 2006, 98, 54-59.	1.6	190
165	Clinical impact of direct referral to primary percutaneous coronary intervention following pre-hospital diagnosis of ST-elevation myocardial infarction. European Heart Journal, 2006, 27, 1550-1557.	2.2	86
166	Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents. American Journal of Cardiology, 2005, 95, 167-172.	1.6	92
167	Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy). American Journal of Cardiology, 2005, 95, 445-451.	1.6	47
168	Noninvasive Assessment of Coronary Plaque Burden Using Multislice Computed Tomography. American Journal of Cardiology, 2005, 95, 1165-1169.	1.6	72
169	Comparison of Effectiveness of Sirolimus-Eluting Stents Versus Bare Metal Stents for Percutaneous Coronary Intervention in Patients at High Risk for Coronary Restenosis or Clinical Adverse Events. American Journal of Cardiology, 2005, 95, 1409-1414.	1.6	33
170	Preprocedural Levels of C-Reactive Protein and Leukocyte Counts Predict 9-Month Mortality After Coronary Angioplasty for the Treatment of Unprotected Left Main Coronary Artery Stenosis. Circulation, 2005, 112, 2332-2338.	1.6	52
171	Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease. International Journal of Cardiology, 2005, 98, 479-486.	1.7	12
172	Late Outcome After Stenting or Coronary Artery Bypass Surgery for the Treatment of Multivessel Disease: A Single-Center Matched-Propensity Controlled Cohort Study. Annals of Thoracic Surgery, 2005, 79, 1563-1569.	1.3	36
173	Fluvastatin reduces the impact of diabetes on long-term outcome after coronary interventionâ€”A Lescol Intervention Prevention Study (LIPS) substudy. American Heart Journal, 2005, 149, 329-335.	2.7	28
174	Drug-eluting stents. The third revolution in percutaneous coronary intervention. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2005, 6, 289-303.	0.1	2
175	Emergency balloon aortic valvuloplasty in patients with critical aortic stenosis presenting with cardiogenic shock. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2005, 6, 420-3.	0.1	1
176	Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the â€œReal Worldâ€. Circulation, 2004, 109, 190-195.	1.6	511
177	Clinical, Angiographic, and Procedural Predictors of Angiographic Restenosis After Sirolimus-Eluting Stent Implantation in Complex Patients. Circulation, 2004, 109, 1366-1370.	1.6	305
178	Incidence of High-Strain Patterns in Human Coronary Arteries. Circulation, 2004, 109, 2716-2719.	1.6	158
179	Effect of fluvastatin on long-term outcome after coronary revascularization with stent implantation. American Journal of Cardiology, 2004, 93, 92-95.	1.6	12
180	Treatment of very small vessels with 2.25-mm diameter sirolimus-eluting stents (from the RESEARCH) Tj ETQq0 0 0,rgBT /Overlock 10 Tf	1.6	51

#	ARTICLE	IF	CITATIONS
181	Very long sirolimus-eluting stent implantation for de novo coronary lesions. American Journal of Cardiology, 2004, 93, 826-829.	1.6	91
182	Incidence of thrombotic stent occlusion during the first three months after sirolimus-eluting stent implantation in 500 consecutive patients. American Journal of Cardiology, 2004, 93, 1271-1275.	1.6	46
183	Effectiveness of sirolimus-Eluting stent implantation for coronary narrowings <50% in diameter. American Journal of Cardiology, 2004, 94, 112-114.	1.6	12
184	Restenosis rates following bifurcation stenting with sirolimus-eluting stents for de novo narrowings. American Journal of Cardiology, 2004, 94, 115-118.	1.6	124
185	Fluvastatin Reduces Cardiac Mortality in Patients with Coronary Heart Disease. Cardiovascular Drugs and Therapy, 2004, 18, 67-75.	2.6	8
186	Stent fracture and restenosis in the drug-eluting stent era. Catheterization and Cardiovascular Interventions, 2004, 61, 111-116.	1.7	184
187	Clinical and angiographic outcomes after overdilatation of undersized sirolimus-eluting stents with largely oversized balloons: An observational study. Catheterization and Cardiovascular Interventions, 2004, 61, 455-460.	1.7	17
188	Elective sirolimus-eluting stent implantation for left main coronary artery disease: Six-month angiographic follow-up and 1-year clinical outcome. Catheterization and Cardiovascular Interventions, 2004, 62, 292-296.	1.7	44
189	Clinical outcomes for sirolimus-eluting stent implantation and vascular brachytherapy for the treatment of in-stent restenosis. Catheterization and Cardiovascular Interventions, 2004, 62, 283-288.	1.7	50
190	Elective sirolimus-eluting stent implantation for multivessel disease involving significant LAD stenosis: One-year clinical outcomes of 99 consecutive patients?the Rotterdam experience. Catheterization and Cardiovascular Interventions, 2004, 63, 57-60.	1.7	16
191	Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. Journal of the American College of Cardiology, 2004, 43, 704-708.	2.8	191
192	Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions. Journal of the American College of Cardiology, 2004, 43, 1954-1958.	2.8	194
193	Multislice spiral computed tomography coronary angiography in patients with stable angina pectoris. Journal of the American College of Cardiology, 2004, 43, 2265-2270.	2.8	376
194	Effectiveness of the sirolimus-eluting stent in the treatment of patients with a prior history of coronary artery bypass graft surgery. Coronary Artery Disease, 2004, 15, 171-175.	0.7	6
195	Long-term outcome of percutaneous coronary interventions following failed beta-brachytherapy. Journal of Invasive Cardiology, 2004, 16, 60-4.	0.4	8
196	Effectiveness of sirolimus-eluting stent implantation for recurrent in-stent restenosis after brachytherapy. American Journal of Cardiology, 2003, 92, 200-203.	1.6	51
197	Effectiveness of sirolimus-eluting stent for treatment of left main coronary artery disease. American Journal of Cardiology, 2003, 92, 327-329.	1.6	68
198	Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes. Journal of the American College of Cardiology, 2003, 41, 2093-2099.	2.8	150

#	ARTICLE	IF	CITATIONS
199	Sirolimus-Eluting Stent Implantation in ST-Elevation Acute Myocardial Infarction. Circulation, 2003, 108, 1927-1929.	1.6	110
200	Coronary Restenosis After Sirolimus-Eluting Stent Implantation. Circulation, 2003, 108, 257-260.	1.6	268
201	Coronary stenting for unstable angina. Coronary Artery Disease, 1999, 10, 81-88.	0.7	2